Advertisement
U.S. markets open in 5 hours 55 minutes

DURECT Corporation (DRRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3500+0.0600 (+4.65%)
At close: 04:00PM EDT
1.3000 -0.05 (-3.70%)
After hours: 06:11PM EDT

DURECT Corporation

10260 Bubb Road
Cupertino, CA 95014-4166
United States
408 777 1417
https://www.durect.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Dr. James E. Brown D.V.M.Co-Founder, CEO, President & Director885.86kN/A1957
Ms. Judy R. JoiceSenior Vice President of Operations & Corporate Quality Assurance451.82kN/A1957
Dr. Norman L. Sussman M.D.Chief Medical Officer587.95kN/A1953
Mr. Timothy M. Papp M.B.A.CFO & SecretaryN/AN/A1976
Ms. Jian Li M.B.A.Interim Principal Accounting Officer, Senior VP of Finance, Corporate Controller & Secretary297.08k16.41k1970
Dr. WeiQi Lin M.D., Ph.D.Executive VP of Research & Development and Principal ScientistN/AN/AN/A
Mr. Keith L. Lui M.B.A.Senior Vice President of Business Development, Commercial & Medical AffairsN/AN/AN/A
Dr. Su Il Yum Ph.D.Executive Officer331.74k62.44k1939
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Corporate Governance

DURECT Corporation’s ISS Governance QualityScore as of March 1, 2024 is 5. The pillar scores are Audit: 9; Board: 2; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.